Tiotropium (Spiriva Respimat) Gets Asthma Indication in USTiotropium (Spiriva Respimat) Gets Asthma Indication in US

The FDA approved a once-daily dose, delivered in two puffs, for long-term maintenance treatment of asthma in people aged 12 years and older. FDA Approvals
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Pulmonary Medicine News Alert Source Type: news